PharmGKB summary: very important pharmacogene information for UGT1A1.
作者信息
Barbarino Julia M, Haidar Cyrine E, Klein Teri E, Altman Russ B
机构信息
Departments of aGenetics bBioengineering, Stanford University, Palo Alto, California, USA cDepartment of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
出版信息
Pharmacogenet Genomics. 2014 Mar;24(3):177-83. doi: 10.1097/FPC.0000000000000024.
Abstract
摘要
相似文献
1
PharmGKB summary: very important pharmacogene information for UGT1A1.药物基因组知识库总结：UGT1A1的非常重要的药物基因信息。
Pharmacogenet Genomics. 2014 Mar;24(3):177-83. doi: 10.1097/FPC.0000000000000024.
2
Pharmacogenetics and irinotecan therapy.药物遗传学与伊立替康治疗
Am J Health Syst Pharm. 2006 Nov 15;63(22):2211-7. doi: 10.2146/ajhp060155.
3
UGT1A1, UGT1A6 and UGT1A7 genetic analysis: repercussion for irinotecan pharmacogenetics in the São Miguel Island Population (Azores, Portugal).UGT1A1、UGT1A6 和 UGT1A7 基因分析：对圣米格尔岛人群（葡萄牙亚速尔群岛）伊立替康药物遗传学的影响。
Mol Diagn Ther. 2009;13(4):261-8. doi: 10.2165/11317170-000000000-00000.
4
PharmGKB summary: very important pharmacogene information for GSTT1.PharmGKB 总结： GSTT1 非常重要的药物基因信息。
Pharmacogenet Genomics. 2012 Aug;22(8):646-51. doi: 10.1097/FPC.0b013e3283527c02.
5
PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.药物基因组知识库摘要：关于人类白细胞抗原B的非常重要的药物基因信息。
Pharmacogenet Genomics. 2015 Apr;25(4):205-21. doi: 10.1097/FPC.0000000000000118.
6
UGT genotyping in belinostat dosing.贝利司他给药中的尿苷二磷酸葡萄糖醛酸基转移酶基因分型
Pharmacol Res. 2016 Mar;105:22-7. doi: 10.1016/j.phrs.2016.01.002. Epub 2016 Jan 7.
7
Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity.尿苷二磷酸葡萄糖醛酸基转移酶1A1基因的苯巴比妥反应增强子模块中的基因多态性与伊立替康毒性
Pharmacogenet Genomics. 2005 Jan;15(1):35-41. doi: 10.1097/01213011-200501000-00006.
8
An overview of the recent progress in irinotecan pharmacogenetics.伊立替康药物遗传学的最新研究进展概述。
Pharmacogenomics. 2010 Mar;11(3):391-406. doi: 10.2217/pgs.10.19.
9
Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan.伊立替康的药物遗传学：UGT1A1基因启动子多态性与伊立替康严重不良反应
Invest New Drugs. 2005 Dec;23(6):539-45. doi: 10.1007/s10637-005-4022-6.
10
Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.UDP-葡萄糖醛酸转移酶多态性与药物剂量相关性：定量系统评价。
Pharmacol Ther. 2014 Jan;141(1):92-116. doi: 10.1016/j.pharmthera.2013.09.002. Epub 2013 Sep 27.
引用本文的文献
1
Molecular landscape of non-driver genes in myeloproliferative neoplasms through 333 cancer genes panel: Insights to reveal in Pakistan.通过333个癌症基因检测分析骨髓增殖性肿瘤中非驱动基因的分子图谱：巴基斯坦的研究启示
BMC Med Genomics. 2025 Aug 4;18(1):125. doi: 10.1186/s12920-025-02159-8.
2
Circulating Bilirubin Levels, but Not Their Genetic Determinants, Are Inversely Associated with Steatotic Liver Disease in Adolescents.循环胆红素水平而非其遗传决定因素与青少年脂肪性肝病呈负相关。
Int J Mol Sci. 2025 Mar 25;26(7):2980. doi: 10.3390/ijms26072980.
3
Managing Irinotecan-Induced Diarrhea: A Comprehensive Review of Therapeutic Interventions in Cancer Treatment.管理伊立替康所致腹泻：癌症治疗中治疗干预措施的全面综述
Pharmaceuticals (Basel). 2025 Mar 2;18(3):359. doi: 10.3390/ph18030359.
4
Mechanisms of altered hepatic drug disposition during pregnancy: small molecules.孕期肝脏药物处置改变的机制：小分子
Expert Opin Drug Metab Toxicol. 2025 Apr;21(4):445-462. doi: 10.1080/17425255.2025.2470792. Epub 2025 Feb 26.
5
Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer.基于转移性三阴性乳腺癌中的应用，加拿大专家关于 Sacituzumab Govitecan 的安全性概述和毒性管理策略的建议。
Curr Oncol. 2024 Sep 21;31(9):5694-5708. doi: 10.3390/curroncol31090422.
6
Genetic variation in is not associated with altered liver biochemical parameters in healthy volunteers participating in bioequivalence trials.参与生物等效性试验的健康志愿者中，[具体基因]的基因变异与肝脏生化参数改变无关。 （你提供的原文中“in”后面缺少具体内容，请补充完整以便更准确翻译）
Front Pharmacol. 2024 May 3;15:1389968. doi: 10.3389/fphar.2024.1389968. eCollection 2024.
7
Genetic variations underlying Gilbert syndrome and HBV infection outcomes: a cross-sectional study.吉尔伯特综合征与乙肝病毒感染结局的潜在基因变异：一项横断面研究。
Front Genet. 2023 Nov 6;14:1265268. doi: 10.3389/fgene.2023.1265268. eCollection 2023.
8
Pharmacogenomic variation in the Malagasy population: implications for the antimalarial drug primaquine metabolism.马达加斯加人群的药物基因组学变异：对抗疟药物伯氨喹代谢的影响。
Pharmacogenomics. 2023 Jul;24(11):583-597. doi: 10.2217/pgs-2023-0091. Epub 2023 Aug 8.
9
Irinotecan dose reduction in metastatic colorectal cancer patients with homozygous polymorphism: a single-center case series.伊立替康剂量减少在伴有纯合子多态性的转移性结直肠癌患者中：一项单中心病例系列研究。
J Int Med Res. 2022 Jul;50(7):3000605221110697. doi: 10.1177/03000605221110697.
10
Germline variants in cancer therapy.癌症治疗中的种系变异
Cancer Drug Resist. 2019 Mar 19;2(1):18-30. doi: 10.20517/cdr.2019.05. eCollection 2019.
本文引用的文献
1
Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.优化 UGT1A 单倍型与以氟尿嘧啶/伊立替康为基础方案治疗转移性结直肠癌患者中伊立替康诱导的血液学毒性的关系。
J Pharmacol Exp Ther. 2013 Apr;345(1):95-101. doi: 10.1124/jpet.112.202242. Epub 2013 Feb 5.
2
Importance of UDP-glucuronosyltransferases 2A2 and 2A3 in tobacco carcinogen metabolism.UDP-葡糖醛酸基转移酶 2A2 和 2A3 在烟草致癌物代谢中的重要性。
Drug Metab Dispos. 2013 Jan;41(1):170-9. doi: 10.1124/dmd.112.049171. Epub 2012 Oct 18.
3
Genetically elevated bilirubin and risk of ischaemic heart disease: three Mendelian randomization studies and a meta-analysis.胆红素水平升高与缺血性心脏病风险的关联：三项孟德尔随机化研究和一项荟萃分析。
J Intern Med. 2013 Jan;273(1):59-68. doi: 10.1111/j.1365-2796.2012.02576.x. Epub 2012 Aug 20.
4
Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer.UGT1A1基因启动子长度多态性与散发性结直肠癌风险
Cancer Genet. 2012 Apr;205(4):163-7. doi: 10.1016/j.cancergen.2012.01.015.
5
Association between bilirubin and cardiovascular disease risk factors: using Mendelian randomization to assess causal inference.胆红素与心血管疾病危险因素的关系：使用孟德尔随机化评估因果关系。
BMC Cardiovasc Disord. 2012 Mar 14;12:16. doi: 10.1186/1471-2261-12-16.
6
Gilbert syndrome.吉尔伯特综合征。
Eur J Pediatr. 2012 Jan;171(1):11-5. doi: 10.1007/s00431-011-1641-0. Epub 2011 Dec 9.
7
Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil.简短通讯：UGT1A1*28变异等位基因是巴西南部接受高效抗逆转录病毒治疗的HIV感染患者发生严重高胆红素血症的一个预测指标。
AIDS Res Hum Retroviruses. 2012 Sep;28(9):1015-8. doi: 10.1089/AID.2011.0261. Epub 2012 May 3.
8
Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study.绝经后血清性激素与激素受体阳性和阴性乳腺癌风险：巢式病例对照研究。
Cancer Prev Res (Phila). 2011 Oct;4(10):1626-35. doi: 10.1158/1940-6207.CAPR-11-0090. Epub 2011 Aug 2.
9
Pharmacogenetics: from bench to byte--an update of guidelines.药物遗传学：从实验室到字节——指南更新。
Clin Pharmacol Ther. 2011 May;89(5):662-73. doi: 10.1038/clpt.2011.34. Epub 2011 Mar 16.
10
Serum bilirubin links UGT1A1*28 polymorphism and predicts long-term cardiovascular events and mortality in chronic hemodialysis patients.血清胆红素与 UGT1A1*28 多态性相关，并可预测慢性血液透析患者的长期心血管事件和死亡率。
Clin J Am Soc Nephrol. 2011 Mar;6(3):567-74. doi: 10.2215/CJN.06130710.
Zotero 插件